1-11 of 11
Carla de Boer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2

Herve Avet Loiseau, Pieter Sonneveld, Philippe Moreau, Fritz Offner, Vincent H.J. van der Velden, Denis Caillot, Cyrille Hulin, Bertrand Arnulf, Jill Corre, Mohamad Mohty, Lionel Karlin, Jérôme Lambert, Margaret Macro, Aurore Perrot, Mark-David Levin, Saskia K. Klein, Anne-Marie Stoppa, Michel Delforge, Sonja Zweegman, Kon-Siong Jie, Niels W.C.J. Van De Donk, Maria Krevvata, Fabio Rigat, Shiyi Yang, Veronique Vanquickelberghe, Carla de Boer, Tobias Kampfenkel, Jessica Vermeulen, Soraya Wuillème, Annemiek Broyl, Marie C Bene
Journal: Blood
Blood (2021) 138 (Supplement 1): 82.
https://doi.org/10.1182/blood-2021-147897
Published: 2021
Journal Articles

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Clinical Trials & Observations
Peter M. Voorhees, Jonathan L. Kaufman, Jacob Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J. Costa, Larry D. Anderson, Jr, Nitya Nathwani, Nina Shah, Yvonne A. Efebera, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Sean Murphy, Yana Lutska, Huiling Pei, Jon Ukropec, Jessica Vermeulen, Carla de Boer, Daniela Hoehn, Thomas S. Lin, Paul G. Richardson
Journal: Blood
Blood (2020) 136 (8): 936–945.
https://doi.org/10.1182/blood.2020005288
Published: 2020
Includes: Supplemental data
Journal Articles

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Peter M. Voorhees, MD, Jonathan L. Kaufman, MD, Jacob P. Laubach, MD, Douglas W. Sborov, MD MSc, Brandi Reeves, MD, Cesar Rodriguez, MD, Ajai Chari, MD, Rebecca W. Silbermann, MD, Luciano J. Costa, MD PhD, Larry D. Anderson, MD PhD, Nitya Nathwani, MD, Nina D. Shah, MD, Yvonne A. Efebera, MD MPH, Caitlin L. Costello, MD, Andrzej Jakubowiak, MD PhD, Tanya M. Wildes, MD, Robert Z. Orlowski, MD PhD, Kenneth H. Shain, MD PhD, Andrew J. Cowan, MD, Sean Murphy, Yana Lutska, PharmD, Huiling Pei, PhD, Jon Ukropec, PhD, Jessica Vermeulen, MD PhD, Carla de Boer, Daniela Hoehn, MD PhD, Thomas S. Lin, MD PhD, Paul G. Richardson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 691.
https://doi.org/10.1182/blood-2019-123465
Published: 2019
Journal Articles

Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

Philippe Moreau, MD, Sonja Zweegman, Aurore Perrot, MD PhD, Cyrille Hulin, MD, Denis Caillot, MD, Thierry Facon, MD, Xavier Leleu, MD PhD, Karim Belhadj, Lionel Karlin, MD, Lotfi Benboubker, MD, Mark-David Levin, MD PhD, Monique C. Minnema, MD PhD, Bastien Jamet, Caroline Bodet-Milin, Pieter Sonneveld, Jérôme Lambert, Lixia Pei, Carla de Boer, Jessica Vermeulen, MD PhD, Tobias Kampfenkel, MD, Francoise Kraeber-Bodere
Journal: Blood
Blood (2019) 134 (Supplement_1): 692.
https://doi.org/10.1182/blood-2019-123143
Published: 2019
Journal Articles

Comparative Efficacy and Safety of Bortezomib, Thalidomide, and Dexamethasone (VTd) without and with Daratumumab (D-VTd) from Cassiopeia Versus Vtd from Pethema/GEM in Patients with Newly Diagnosed Multiple Myeloma Using Propensity Score Matching (PSM)

Philippe Moreau, MD, Cyrille Hulin, MD, Sonja Zweegman, MD PhD, Yannan Hu, PhD, Bart Heeg, PhD, Mahmoud Hashim, Carla de Boer, Veronique Vanquickelberghe, Tobias Kampfenkel, MD, Annette Lam, Sarah Cote, Pieter Sonneveld
Journal: Blood
Blood (2019) 134 (Supplement_1): 4740.
https://doi.org/10.1182/blood-2019-123491
Published: 2019
Journal Articles

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Clinical Trials & Observations
Ajai Chari, Joaquín Martinez-Lopez, María-Victoria Mateos, Joan Bladé, Lotfi Benboubker, Albert Oriol, Bertrand Arnulf, Paula Rodriguez-Otero, Luis Pineiro, Andrzej Jakubowiak, Carla de Boer, Jianping Wang, Pamela L. Clemens, Jon Ukropec, Jordan Schecter, Sagar Lonial, Philippe Moreau
Journal: Blood
Blood (2019) 134 (5): 421–431.
https://doi.org/10.1182/blood.2019000722
Published: 2019
Journal Articles

Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001

Thierry Facon, Sagar Lonial, MD, Brendan M Weiss, MD, Attaya Suvannasankha, MD, Joseph Fay, Bertrand Arnulf, Jainulabdeen J Ifthikharuddin, Carla de Boer, Jianping Wang, Kaida Wu, Ajai Chari, Suzanne Lentzsch, Jordan Schecter, Amrita Krishnan, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1824.
https://doi.org/10.1182/blood.V130.Suppl_1.1824.1824
Published: 2017
Journal Articles

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (GEN503): Final Results of an Open-Label, Phase 1/2 Study

Torben Plesner, MD, Hendrik-Tobias Arkenau, Francesca Marianatal Gay, Monique C Minnema, Mario Boccadoro, Philippe Moreau, MDPhD, James D Cavenagh, Aurore Perrot, MD, Jacob Laubach, MD, Tahamtan Ahmadi, Carla de Boer, Diana Chen, Christopher Chiu, Jordan Schecter, Paul G Richardson, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1828.
https://doi.org/10.1182/blood.V130.Suppl_1.1828.1828
Published: 2017
Journal Articles

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

Clinical Trials & Observations
Torben Plesner, Hendrik-Tobias Arkenau, Peter Gimsing, Jakub Krejcik, Charlotte Lemech, Monique C. Minnema, Ulrik Lassen, Jacob P. Laubach, Antonio Palumbo, Steen Lisby, Linda Basse, Jianping Wang, A. Kate Sasser, Mary E. Guckert, Carla de Boer, Nushmia Z. Khokhar, Howard Yeh, Pamela L. Clemens, Tahamtan Ahmadi, Henk M. Lokhorst, Paul G. Richardson
Journal: Blood
Blood (2016) 128 (14): 1821–1828.
https://doi.org/10.1182/blood-2016-07-726729
Published: 2016
Includes: Supplemental data
Journal Articles

A Phase 1 Study Of JNJ-40346527, a Colony Stimulating Factor-1 Receptor (CSF-1R) Inhibitor, In Patients With Relapsed Or Refractory Hodgkin Lymphoma

Bastian von Tresckow, MD, Franck Morschhauser, MD, PhD, Vincent Ribrag, Max S. Topp, MD, Caly Chien, PhD, Shobha Seetharam, PhD, Regina Aquino, BS, Sonja Kotoulek, BS, Imran Khan, MD, PhD, Carla de Boer, PhD, Andreas Engert, MD
Journal: Blood
Blood (2013) 122 (21): 1812.
https://doi.org/10.1182/blood.V122.21.1812.1812
Published: 2013
Journal Articles

Assessment of Two Doses of Infliximab in Patients with Low/Intermediate Risk IPSS Myelodysplastic Syndrome (MDS): An EORTC Leukemia Group (LG) Randomized Phase II Trial (06023).

Liliana Baila, Stefan Suciu, Petra Muus, Sergio Amadori, Michel Delforge, Gert Ossenkoppele, Dominik L.D. Selleslag, Antoine Thyss, Hilde Demuynk, Alain Gadisseur, P. Vermeulen, Carla De Boer, Heinz Zwierzina, T.M. de Witte
Journal: Blood
Blood (2007) 110 (11): 1456.
https://doi.org/10.1182/blood.V110.11.1456.1456
Published: 2007